Literature DB >> 18462408

Review article: hypertonic saline use in the emergency department.

Colin J Banks1, Jeremy S Furyk.   

Abstract

Hypertonic saline (HS) is being increasingly used for the management of a variety of conditions, most notably raised intracranial pressure. This article reviews the available evidence on HS solutions as they relate to emergency medicine, and develops a set of recommendations for its use. To conclude, HS is recommended as an alternative to mannitol for treating raised intracranial pressure in traumatic brain injury. HS is also recommended for treating severe and symptomatic hyponatremia, and is worth considering for both recalcitrant tricyclic antidepressant toxicity and for cerebral oedema complicating paediatric diabetic ketoacidosis. HS is not recommended for hypovolaemic resuscitation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18462408     DOI: 10.1111/j.1742-6723.2008.01086.x

Source DB:  PubMed          Journal:  Emerg Med Australas        ISSN: 1742-6723            Impact factor:   2.151


  3 in total

1.  Management of bleeding following major trauma: an updated European guideline.

Authors:  Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Philip F Stahel; Jean-Louis Vincent; Donat R Spahn
Journal:  Crit Care       Date:  2010-04-06       Impact factor: 9.097

2.  The currency, completeness and quality of systematic reviews of acute management of moderate to severe traumatic brain injury: A comprehensive evidence map.

Authors:  Anneliese Synnot; Peter Bragge; Carole Lunny; David Menon; Ornella Clavisi; Loyal Pattuwage; Victor Volovici; Stefania Mondello; Maryse C Cnossen; Emma Donoghue; Russell L Gruen; Andrew Maas
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

Review 3.  ROC trials update on prehospital hypertonic saline resuscitation in the aftermath of the US-Canadian trials.

Authors:  Michael A Dubick; Pang Shek; Charles E Wade
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.